Skip to main content
. Author manuscript; available in PMC: 2022 Aug 13.
Published in final edited form as: Anticancer Res. 2018 Jul;38(7):4035–4039. doi: 10.21873/anticanres.12692

Table I.

Baseline characteristics.

N (%)
Age (median, range), years 70 (44–90)
Gender
 Male 10 (31%)
 Female 22 (68%)
ECOG performance status
 0 5 (16%)
 1 21 (66%)
 2 4 (13%)
 3 2 (6%)
Reason for neoadjuvant therapy
 Unresectable 10 (31%)
 Borderline resectable 16 (50%)
 Resectable but comorbidities 6 (19%)
Requiring biliary stent
 Yes 21 (66%)
 No 11 (34%)